Haemonetics Valuation
| HAE Stock | USD 80.15 0.83 1.02% |
At this time, the firm appears to be undervalued. Haemonetics retains a regular Real Value of $87.33 per share. The prevalent price of the firm is $80.15. Our model calculates the value of Haemonetics from evaluating the firm fundamentals such as Return On Equity of 0.19, current valuation of 4.68 B, and Return On Asset of 0.0636 as well as inspecting its technical indicators and probability of bankruptcy.
Undervalued
Today
Please note that Haemonetics' price fluctuation is very steady at this time. Calculation of the real value of Haemonetics is based on 3 months time horizon. Increasing Haemonetics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Haemonetics stock is determined by what a typical buyer is willing to pay for full or partial control of Haemonetics. Since Haemonetics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Haemonetics Stock. However, Haemonetics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 80.15 | Real 87.33 | Hype 80.15 | Naive 84.72 |
The real value of Haemonetics Stock, also known as its intrinsic value, is the underlying worth of Haemonetics Company, which is reflected in its stock price. It is based on Haemonetics' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Haemonetics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Haemonetics helps investors to forecast how Haemonetics stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Haemonetics more accurately as focusing exclusively on Haemonetics' fundamentals will not take into account other important factors: Haemonetics Total Value Analysis
Haemonetics is currently forecasted to have company total value of 4.68 B with market capitalization of 3.86 B, debt of 1.22 B, and cash on hands of 306.76 M. Please note that company total value may be misleading and is a subject to accounting gimmicks. We encourage investors to carefully check all of the Haemonetics fundamentals before making security assessment based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
4.68 B | 3.86 B | 1.22 B | 306.76 M |
Haemonetics Investor Information
About 99.0% of the company shares are owned by institutional investors. The book value of Haemonetics was currently reported as 18.17. The company has Price/Earnings To Growth (PEG) ratio of 1.23. Haemonetics had not issued any dividends in recent years. The entity had 2:1 split on the 3rd of December 2012. Based on the key indicators related to Haemonetics' liquidity, profitability, solvency, and operating efficiency, Haemonetics is not in a good financial situation at the moment. It has a very high risk of going through financial straits in February.Haemonetics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Haemonetics has an asset utilization ratio of 55.52 percent. This indicates that the Company is making $0.56 for each dollar of assets. An increasing asset utilization means that Haemonetics is more efficient with each dollar of assets it utilizes for everyday operations.Haemonetics Ownership Allocation
The majority of Haemonetics outstanding shares are owned by outside corporations. These institutional investors are usually referred to as non-private investors looking to purchase positions in Haemonetics to benefit from reduced commissions. Consequently, third-party entities are subject to a different set of regulations than regular investors in Haemonetics. Please pay attention to any change in the institutional holdings of Haemonetics as this could imply that something significant has changed or is about to change at the company.Haemonetics Profitability Analysis
The company reported the last year's revenue of 1.36 B. Total Income to common stockholders was 167.68 M with profit before taxes, overhead, and interest of 790.03 M.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Haemonetics' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Haemonetics and how it compares across the competition.
About Haemonetics Valuation
The stock valuation mechanism determines Haemonetics' current worth on a weekly basis. Our valuation model uses a comparative analysis of Haemonetics. We calculate exposure to Haemonetics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Haemonetics's related companies.Haemonetics Corporation, a healthcare company, provides medical products and solutions. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts. Haemonetics Corp operates under Medical Instruments Supplies classification in the United States and is traded on New York Stock Exchange. It employs 2821 people.
Haemonetics Growth Indicators
Investing in growth stocks can be very risky. If the company such as Haemonetics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 50.7 M | |
| Quarterly Earnings Growth Y O Y | 0.227 | |
| Forward Price Earnings | 14.7059 |
Complementary Tools for Haemonetics Stock analysis
When running Haemonetics' price analysis, check to measure Haemonetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Haemonetics is operating at the current time. Most of Haemonetics' value examination focuses on studying past and present price action to predict the probability of Haemonetics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Haemonetics' price. Additionally, you may evaluate how the addition of Haemonetics to your portfolios can decrease your overall portfolio volatility.
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |